首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   620篇
  免费   205篇
  国内免费   2篇
耳鼻咽喉   2篇
儿科学   27篇
妇产科学   56篇
基础医学   25篇
口腔科学   5篇
临床医学   248篇
内科学   153篇
皮肤病学   13篇
神经病学   36篇
特种医学   35篇
外科学   68篇
综合类   4篇
预防医学   80篇
眼科学   3篇
药学   17篇
肿瘤学   55篇
  2024年   3篇
  2023年   25篇
  2022年   11篇
  2021年   29篇
  2020年   31篇
  2019年   13篇
  2018年   46篇
  2017年   46篇
  2016年   46篇
  2015年   48篇
  2014年   53篇
  2013年   53篇
  2012年   40篇
  2011年   32篇
  2010年   30篇
  2009年   49篇
  2008年   18篇
  2007年   28篇
  2006年   31篇
  2005年   8篇
  2004年   17篇
  2003年   6篇
  2002年   16篇
  2001年   17篇
  2000年   12篇
  1999年   10篇
  1998年   15篇
  1997年   18篇
  1996年   14篇
  1995年   7篇
  1994年   5篇
  1993年   3篇
  1992年   5篇
  1991年   6篇
  1990年   4篇
  1989年   4篇
  1988年   4篇
  1987年   2篇
  1986年   2篇
  1985年   3篇
  1981年   2篇
  1980年   3篇
  1979年   1篇
  1978年   1篇
  1977年   2篇
  1976年   3篇
  1975年   1篇
  1970年   2篇
  1968年   1篇
  1967年   1篇
排序方式: 共有827条查询结果,搜索用时 653 毫秒
1.
Milieu relationships provide the critical background presence to staff's attempts to motivate, regulate, and teach patients how to cope with stress. Forging a connection with hospitalized children and adolescents demands attention to how they respond to adults and engage with staff around milieu expectations. Assessment guides that deal with these issues are presented. Important aspects of children's relatedness are presented in the context of their working models of adults and the influence of these representations on their response to staff. Coping skills are explained with particular emphasis on behavioral coping strategies. Tied to the assessment process are interventions that emphasize staff's role in helping patients manage strong affects and avoid the use of nonproductive behavior regulation strategies.  相似文献   
2.
3.
4.
5.
Follistatin and activin A production by the male reproductive tract   总被引:1,自引:0,他引:1  
Follistatin is a binding protein for the activin and inhibin family of hormones, regulating their biological activity. In the male reproductive tract, the interaction of these factors is likely to be involved in the regulation of the proliferation of several cell types. We have investigated the presence of follistatin and activin A in seminal plasma using specific immunoassays and have localized follistatin and activin/inhibin subunits in the adult human testis, prostate and seminal vesicle to establish their likely sources. High concentrations of immunoreactive follistatin were present in seminal plasma in normal men (mean 97.9 ng/ml; 1.43 ng/ml in peripheral plasma) and were similar in men with oligo/azoospermia and following vasectomy. Follistatin immunoreactivity was localized to both Leydig and Sertoli cells of the testis, and to epithelial cells of the prostate gland and seminal vesicle, which are likely to be the predominant sources of the hormone in seminal plasma. Activin A was also present in seminal plasma in normal men but was undetectable following vasectomy, thus deriving from the testis. Consistent with this finding, the betaA-subunit was immunolocalized in Sertoli and Leydig cells but was not present in seminal vesicle or prostate gland. The functional significance of the high concentrations of follistatin secreted into seminal plasma by the prostate gland and/or seminal vesicle is uncertain, but they may regulate the biological activity of testis-derived activin A and inhibin B.   相似文献   
6.
7.
8.
Maternal serum concentrations of inhibin-A, inhibin-B, activin-A, activin-AB, pro-alphaC-related inhibin forms, total follistatin, steroids and gonadotrophins were measured longitudinally in six normal singleton pregnancies. Maternal venous blood was collected randomly during a spontaneous follicular phase prior to donor insemination, at 5, 7, 9, 11, 16, 20, 24, 28, 32 and 36 weeks after the first missed menses and in the early puerperium. Steroid and gonadotrophin profiles conformed to previous reports. While at week 5 of gestation inhibin-A, activin-A and follistatin concentrations were similar to those at the follicular phase, all three increased progressively (P < 0.001) to maximal concentrations in week 36: approximately 48-fold (3740 +/- 1349 ng inhibin-A/ml), approximately 22-fold (6109 +/- 1443 ng activin-A/ml) and approximately 10-fold (3563 +/- 418 ng follistatin/ml) higher. Pro- alphaC concentrations reached a maximum in weeks 5 (approximately 5- fold, P < 0.001) and 36 (1027 +/- 174 pg/ml, P < 0.01). Inhibin-B (71 +/- 23 pg/ml prior to pregnancy) was undetectable (<12 pg/ml) between week 5-16 of gestation but increased slightly in the third trimester (26 +/- 7 pg/ml in week 36). Activin-AB was undetectable throughout pregnancy. Post-partum concentrations of inhibin-A (41 +/- 12 ng/ml), inhibin-B (<12 pg/ml), activin-A (950 +/- 149 pg/ml), pro-alphaC (128 +/- 22 pg/ml) and follistatin (990 +/- 79 ng/ml) were substantially lower than at week 36 of gestation. The activin-A:follistatin ratio increased from 0.5 in week 5 to 1.8 in week 36, suggesting that more free activin-A is available in the maternal circulation during late pregnancy.   相似文献   
9.
The purpose of this study was to evaluate the effectiveness of a Navy remedial exercise program (REP) in improving the physical fitness levels of its participants. Subjects were 27 Navy personnel assigned to a Northeast naval air station who had failed to pass either the body composition (circumference measures) or aerobic fitness (1.5-mile run/walk) portion of the semiannual physical readiness test. The REP consisted of three 1-hour supervised exercise sessions per week for 16 weeks, with primary emphasis on running and walking. Paired t tests revealed that the REP was effective in reducing body weight (-3.1%) and body fat (mean absolute loss of 2.7%) and in improving 1.5-mile run/walk time (-6.2%). No changes were seen in muscular endurance measures (2-minute push-ups, 2-minute curl-ups). Findings from this study indicate that improvements in PF can be attained through a 16-week Navy remedial exercise program.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号